I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, and a deep understanding of technology and innovation in the industry. Today, we’re diving into the groundbreaking world of AI-driven drug discovery, focusing on a
Alzheimer’s disease (AD), the leading cause of dementia worldwide, poses a formidable challenge with its prevalence expected to triple by 2050, placing immense emotional and economic burdens on aging populations across the globe. This neurodegenerative condition, characterized by progressive memory
Imagine a world where the mysteries of life at every scale—from the tiniest molecular interactions to the complex systems of entire organisms—are decoded with unprecedented speed and accuracy, potentially transforming how diseases are understood and treated. This vision is at the heart of a
In a world where complex diseases like cancer and neurodegenerative disorders continue to challenge medical science, a transformative approach is emerging through artificial intelligence (AI). Imagine a tool so precise that it can predict the exact genetic targets needed to reverse a diseased
The world of drug discovery is witnessing a seismic shift as researchers and institutions move away from traditional animal models toward innovative human-based in vitro systems, driven by a pressing need to address the staggering failure rate of drug candidates in clinical trials, which exceeds
Imagine a world where chronic diseases like cardiovascular disorders, metabolic conditions, and autoimmune issues are treated not by altering the very fabric of DNA, but by subtly tweaking how genes are expressed—a safer, more precise approach to healing that could transform countless lives.
